APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G
about
Deaminase-independent inhibition of parvoviruses by the APOBEC3A cytidine deaminaseHIV-1 replication and APOBEC3 antiviral activity are not regulated by P bodiesAPOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-lymphotropic virus type 1Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1Targeting APOBEC3A to the viral nucleoprotein complex confers antiviral activityAPOBEC3G contributes to HIV-1 variation through sublethal mutagenesisHIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factorsHuman LINE-1 restriction by APOBEC3C is deaminase independent and mediated by an ORF1p interaction that affects LINE reverse transcriptase activityRestriction of retroviral replication by APOBEC3G/F and TRIM5alphaHIV-1 Vif, APOBEC, and intrinsic immunityThe range of human APOBEC3H sensitivity to lentiviral Vif proteinsHuman APOBEC3G can restrict retroviral infection in avian cells and acts independently of both UNG and SMUG1Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assemblyIdentification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidationHuman immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integrationExosomes in Human Immunodeficiency Virus Type I Pathogenesis: Threat or Opportunity?Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them allHIV-1 reverse transcriptionSuppression of APOBEC3-mediated restriction of HIV-1 by VifStructural Insights into HIV-1 Vif-APOBEC3F InteractionCrystal Structure of the DNA Cytosine Deaminase APOBEC3F: The Catalytically Active and HIV-1 Vif-Binding DomainMolecular mechanisms underlying occult hepatitis B virus infection.1.92 Angstrom Zinc-Free APOBEC3F Catalytic Domain Crystal StructureRNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1Interaction of APOBEC3A with DNA assessed by atomic force microscopyDifferent mutagenic potential of HIV-1 restriction factors APOBEC3G and APOBEC3F is determined by distinct single-stranded DNA scanning mechanismsFootprint of APOBEC3 on the genome of human retroelementsAPOBEC3G: an intracellular centurionHypermutation of an ancient human retrovirus by APOBEC3GMultiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development.The restriction of zoonotic PERV transmission by human APOBEC3G.T cells contain an RNase-insensitive inhibitor of APOBEC3G deaminase activity.Vpr14-88-Apobec3G fusion protein is efficiently incorporated into Vif-positive HIV-1 particles and inhibits viral infection.APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication.Demonstration of a novel HIV-1 restriction phenotype from a human T cell lineAPOBEC3G inhibits elongation of HIV-1 reverse transcripts.Quantification of deaminase activity-dependent and -independent restriction of HIV-1 replication mediated by APOBEC3F and APOBEC3G through experimental-mathematical investigation.Different modes of retrovirus restriction by human APOBEC3A and APOBEC3G in vivo.Inability of plasmacytoid dendritic cells to directly lyse HIV-infected autologous CD4+ T cells despite induction of tumor necrosis factor-related apoptosis-inducing ligand.Interaction of Vpx and apolipoprotein B mRNA-editing catalytic polypeptide 3 family member A (APOBEC3A) correlates with efficient lentivirus infection of monocytes
P2860
08fc57cc3728cdf80d09b9a423cf4f3eb00e639d160af6fe24dbe8597fba66466b182903d5f0fbf91abadea8c6c96e1b9721e578317c87e3ed1a5b8f610afed84d3d2ba72fad51db456f46396d0bcf6d705eb9000c688de2a3f17e41ddee760e006ea42e7fbaf2d5c6675c111830fd9a36f4fad3542140c59472db9acb324a799d28d1d275c26070dd322fc2a54a2d3f3fa41ff35914843bbd506d984d88de8cec398de9d07bc50bafe68596390dcf630fa30cdc
P248
Q21131577-74B30327-2813-4FFB-85D3-447BD125D23FQ24297395-7C0BC5F0-EA66-4B07-B5CE-6AADDBA9518CQ24310242-5AE4D20F-C17A-46EB-BFD0-2C2219BD73A8Q24321636-AF364786-DCAE-45A3-818A-73EEBD5F3407Q24565021-4ECE1139-A4B8-4945-B22C-682795332129Q24618320-17BF321D-A1D9-4ABF-AE7F-B026D06338ACQ24619114-892BEC08-32E0-4239-9218-85D964ECCF96Q24625056-E6526C88-66C2-42BA-A4BE-2AB3B50619B3Q24630459-905928C9-4ABD-4518-938B-117F7CD0D61DQ24647833-66B27FFC-6BDA-4740-90F7-C67C64A707DBQ24653931-FEC37E6E-1FFC-433E-85EF-83A17E12A6BEQ24655541-D7CBF831-A03D-4904-AA4E-F165B6159017Q24658171-AB265716-B6F0-4020-9D2B-CFEC6A52E2F3Q24672209-0B790603-AD2C-45BF-BCE0-573A1EDA8911Q24684279-5CE3ADFC-7356-4252-B59E-041640FC5E4AQ26765283-D7AFC650-5C35-4520-A8F1-5EC690EA3E1DQ26823568-15326BCB-6801-4DFC-B967-32C93AAFBFA4Q27023387-2199A952-6D3A-4BCF-A0BC-D7C992D32E41Q27025150-F71688A5-73D2-4180-A519-DE6953614B36Q27321018-9FA63D45-E67F-465F-BEC9-4CCA0B53E15AQ27678176-3DBC0C31-B57F-4EBF-9506-1561AE67ABB5Q27686923-FA2F1E6E-3F59-4398-8144-A77124962430Q27704805-55289A93-2A41-4512-BCF5-BD0DB3AEE394Q28474904-9E50E37A-2387-409E-83F6-812611EA3BEFQ28539478-16C7C21E-26C4-4D73-932F-4930699CB904Q28541264-48869F75-073D-481C-9BF6-2036DB76C306Q28680708-2C813BF1-E418-4E68-A719-2E4AAE08DB46Q28754989-FCF1CB62-3418-48B7-A1D7-C9C8EB74EE67Q28757351-A6630F5E-F5B5-4ECA-83E6-84993FAD7EA5Q30381745-C4FDA5D7-25F6-43B4-9B53-AE86C376623EQ33298609-3DD83978-14DA-4647-9955-EC3C78136381Q33300132-95F8268F-F2D3-44AB-8808-88F6333E3C35Q33328499-F4615475-7572-4EC0-A2D3-0E7B682096C5Q33349452-ED272436-3F1C-4C1B-9663-C680F692BA1BQ33355942-8F9495F6-07F6-4A0D-972C-1FA2F7A911A7Q33389841-D3948AAB-4C0A-4E34-92B6-8F5E69825F0DQ33602923-9431BEA9-27E1-441F-A5F6-3CD2E2B4B7A0Q33650603-F26A8407-CDBE-4143-9348-68300921415CQ33676532-A71488F2-71C2-44CE-8386-26D8B2CEFF13Q33782594-8DEDB1A7-D606-4DB2-A449-6D8F8A8BDF5A
P2860
APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
APOBEC3F can inhibit the accum ...... ion. Comparisons with APOBEC3G
@ast
APOBEC3F can inhibit the accum ...... ion. Comparisons with APOBEC3G
@en
APOBEC3F can inhibit the accum ...... ion. Comparisons with APOBEC3G
@en-gb
APOBEC3F can inhibit the accum ...... ion. Comparisons with APOBEC3G
@nl
type
label
APOBEC3F can inhibit the accum ...... ion. Comparisons with APOBEC3G
@ast
APOBEC3F can inhibit the accum ...... ion. Comparisons with APOBEC3G
@en
APOBEC3F can inhibit the accum ...... ion. Comparisons with APOBEC3G
@en-gb
APOBEC3F can inhibit the accum ...... ion. Comparisons with APOBEC3G
@nl
prefLabel
APOBEC3F can inhibit the accum ...... ion. Comparisons with APOBEC3G
@ast
APOBEC3F can inhibit the accum ...... ion. Comparisons with APOBEC3G
@en
APOBEC3F can inhibit the accum ...... ion. Comparisons with APOBEC3G
@en-gb
APOBEC3F can inhibit the accum ...... ion. Comparisons with APOBEC3G
@nl
P2093
P921
P3181
P356
P1476
APOBEC3F can inhibit the accum ...... ion. Comparisons with APOBEC3G
@en
P2093
Fransje A Koning
Kate N Bishop
Rebecca K Holmes
P304
P3181
P356
10.1074/JBC.M607298200
P407
P577
2007-01-26T00:00:00Z